Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Multiple myeloma and other malignancies: a pilot study from the Houston VA.

Munker R, Shi R, Lin D, Guo S, Hayes TG.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):102-6. doi: 10.1016/j.clml.2013.10.006.


A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.

Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ.

Blood. 2012 Mar 22;119(12):2764-7. doi: 10.1182/blood-2011-08-373514. Review.


Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.

Tzeng HE, Lin CL, Tsai CH, Tang CH, Hwang WL, Cheng YW, Sung FC, Chung CJ.

PLoS One. 2013 Jul 2;8(7):e68041. doi: 10.1371/journal.pone.0068041.


Synchronous and metachronous malignancies: analysis of the Minneapolis Veterans Affairs (VA) tumor registry.

Powell S, Tarchand G, Rector T, Klein M.

Cancer Causes Control. 2013 Aug;24(8):1565-73. doi: 10.1007/s10552-013-0233-x.


Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL.

Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0.


Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG.

J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180.


Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.

Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, May AM, Schumacher M, Kleber M, Wäsch R.

Haematologica. 2015 Oct;100(10):1340-9. doi: 10.3324/haematol.2015.127548.


Multiple myeloma and second malignancies.

Engelhardt M, Wäsch R, Landgren O, Kleber M.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):98-101. doi: 10.1016/j.clml.2013.11.008. No abstract available.


Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators..

N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.


Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?

Dasanu CA, Mewawalla P, Grabska J.

Curr Med Res Opin. 2012 Jul;28(7):1129-40. doi: 10.1185/03007995.2012.688800. Review.


Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147.


Observations of second primary malignancy in patients with multiple myeloma.

Ormerod A, Fausel CA, Abonour R, Kiel PJ.

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):113-7. doi: 10.1016/j.clml.2011.11.003.


The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation.

Munker R, Shi R, Nair B, Devarakonda S, Cotelingam JD, McLarty J, Mills GM, Glass J.

Acta Haematol. 2016;135(3):146-55. doi: 10.1159/000440970.


A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.

Xu G, Wang B, Yang M, Qian W.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):15025-9.


Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma.; European Myeloma Network..

Acta Haematol. 2014;132(2):211-9.


Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T.

Haematologica. 2012 May;97(5):784-91. doi: 10.3324/haematol.2011.044271.


Update on second primary malignancies in multiple myeloma: a focused review.

Landgren O, Mailankody S.

Leukemia. 2014 Jul;28(7):1423-6. doi: 10.1038/leu.2014.22. Review.


Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.

Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE.

J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9. doi: 10.1093/jnci/djn394.


Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators..

N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.


[Association of multiple myeloma and solid neoplasms: analysis of 13 cases].

Todolí Parra JA, Campo López C, Segura Huerta A, Alonso Estellés R, Saro Pérez E, Torrego Giménez A, Santaballa Bertrán A, Pastor Borgoñón M, Calabuig Alborch JR.

Rev Clin Esp. 1999 Nov;199(11):725-8. Spanish.

Items per page

Supplemental Content

Support Center